Decheng Capital’s Arcus Biosciences RCUS Stock Holding History

Decheng Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.3M	Sell	464,779 -13,040	-3%	-$322K	1.96%	6
2026 Q1	$10.3M	Sell	477,819 -63,740	-12%	-$1.38M	1.56%	8
2025 Q4	$12.9M	Sell	541,559 -6,050	-1%	-$123K	1.74%	8
2025 Q3	$7.45M	Buy	547,609 +387,609	+242%	+$4.03M	1.3%	11
2025 Q2	$811K	Sell	160,000 -648,789	-80%	-$5.54M	0.2%	19
2025 Q1	$6.35M	Hold	808,789	–	–	1.78%	12
2024 Q4	$12M	Sell	808,789 -61,001	-7%	-$996K	2.58%	6
2024 Q3	$13.3M	Hold	869,790	–	–	3.15%	4
2024 Q2	$13.2M	Hold	869,790	–	–	4.06%	3
2024 Q1	$16.4M	Hold	869,790	–	–	2.2%	6
2023 Q4	$16.6M	Buy	+869,790	New	+$13.9M	4.64%	6

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Decheng Capital's RCUS Position: Q2 2026 in Review

Decheng Capital reduced its Arcus Biosciences (RCUS) stake by 2.7% in Q2 2026, selling an estimated $322K and leaving 464,779 shares worth $14.3M. The position accounts for 1.96% of the portfolio, ranked #6.

Decheng Capital first reported a position in RCUS in Q4 2023 and has held it in 11 quarters since. The position peaked at $16.6M in Q4 2023. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Decheng Capital held 464,779 shares of Arcus Biosciences worth $14.3M as of Q2 2026.
Decheng Capital sold 13,040 Arcus Biosciences shares in Q2 2026, an estimated $322K.
Arcus Biosciences made up 1.96% of Decheng Capital's portfolio in Q2 2026, its #6 holding.
Decheng Capital first reported a position in Arcus Biosciences in Q4 2023 and has held it in 11 quarters since.
Decheng Capital's Arcus Biosciences position peaked at $16.6M in Q4 2023.
232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Decheng Capital's 13F filing for Q2 2026, filed 14 Aug 2026.